


8.2. Propuesta de estrategia de tratamiento farmacológico

ESTRATEGIA DE TRATAMIENTO FARMACOLÓGICO ANTIHIPERTENSIVO PROYECTO "REDUCCIÓN DEL RIESGO CARDIOVASCULAR A TRAVÉS DEL CONTROL DE HIPERTENSIÓN Y PREVENCIÓN SECUNDARIA"



Modificado de: Kaiser Permanente National Hypertension Treatment Care Pathway (<http://kpcmi.org/how-we-work/hypertension-control/>)



IX. REFERENCIAS BIBLIOGRÁFICAS

- 1 Dans AL, Dans LF. Appraising a tool for guideline appraisal (the AGREE II instrument). *J Clin Epidemiol*. 2010 Dec;63(12):1281-2.
- 2 Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. *CMAJ*. 2010 Dec 14;182(18): E839-42.
- 3 Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA*. 2003 May 21;289(19):2560-72.
- 4 Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens*. 2013 Oct;31(10):1925-38.
- 5 Bonet Gorbea M, Varona Pérez P. III Encuesta nacional de factores de riesgo y actividades preventivas de enfermedades no transmisibles. Cuba 2010-2011. Editorial Ciencias Médicas 2014. [citado 10 Nov 2016] disponible en: http://www.bvs.sld.cu/libros/encuesta_nacional_riesgo/indicep.htm
- 6 MINSAP. Dirección de Registros médicos y estadísticas de salud. Anuario estadístico de salud. Cuba 2015. [citado 11 Nov 2016] Disponible en: www.sld.cu/sitios/dne/
- 7 Nordet P, Mendis S, Dueñas A, de la Noval R, Armas N, de la Noval IL, et al. Total Cardiovascular Risk Assessment and Management Using Two Prediction Tools, with and without Blood Cholesterol. *MEDICC Rev*. 2013 Oct;15(4):36-40.
- 8 Armas RNB, de la Noval GR, Dueñas HA, Castillo NJC, Suárez MR, Castillo GA. Estimación del riesgo cardiovascular mediante tablas de la Organización Mundial de la Salud. Área de salud “Héroes del Moncada”. *Rev Cubana Cardiol Cir Cardiovasc*. 2014;20(1).
- 9 de la Noval García R, Armas Rojas NB, de la Noval González I, Fernández González Y, Pupo Rodríguez HB, Dueñas Herrera A, et al. Estimación del riesgo

- cardiovascular global en una población del Área de Salud “Mártires del Corynthia”. La Habana, Cuba. Rev Cubana Cardiol Cir Cardiovasc. 2011;17(1):62-8.
- 10 Varona PP, Armas RNB, Suárez MR, Bonet GM, Dueñas HAF. Estimación del riesgo cardiovascular en la población cubana. Una aproximación al tema. Rev Cubana Cardiol Cir Cardiovasc. 2015;21(4).
 - 11 Elosua R, Morales Salinas A. Determinación del riesgo cardiovascular global. Caracterización, modelización y objetivos de la prevención cardiovascular según el contexto socio-geográfico. Rev Esp Cardiol Supl. 2011;11(E):2-12 <http://www.revespcardiol.org/es/determinacion-del-riesgo-cardiovascular-total-/articulo/90050904/>
 - 12 Parati G, Stergiou GS, Asmar R, Bilo G, de Leeuw P, Imai Y, et al. European Society of Hypertension practice guidelines for home blood pressure monitoring. J Hum Hypertens. 2010 Dec;24(12):779-85.
 - 13 Sehestedt T, Jeppesen J, Hansen TW, Wachtell K, Ibsen H, Torp-Pedersen C, et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J. 2010 Apr;31(7):883-91.
 - 14 Cuspidi C, Ambrosioni E, Mancia G, Pessina AC, Trimarco B, Zanchetti A, et al. Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey. J Hypertens. 2002 Jul;20(7):1307-14.
 - 15 Marwick TH, Gillebert TC, Aurigemma G, Chirinos J, Derumeaux G, Galderisi M, et al. Recommendations on the Use of Echocardiography in Adult Hypertension: A Report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). J Am Soc Echocardiogr. 2015 Jul;28(7):727-54.
 - 16 Lang RM, Badano L, Afilalo J, Chamber Quantification Writing Group, American Society of Echocardiography’s Guidelines, Standards Committee, European Association of Echocardiography. Recommendations for cardiac chamber quantification by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015 Jan;28(1):1-39. e14.

- 17 Ankle Brachial Index Collaboration, Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. *JAMA*. 2008 Jul 9;300(2):197-208.
- 18 Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. *J Am Coll Cardiol*. 2011 May 17;57(20):2037-114.
- 19 Pierce GL, Zhu H, Darracott K, Edet I, Bhagatwala J, Huang Y, et al. Arterial stiffness and pulse-pressure amplification in overweight/obese African-American adolescents: relation with higher systolic and pulse pressure. *Am J Hypertens*. 2013 Jan;26(1):20-6.
- 20 Nambi V, Chambless L, Folsom AR, He M, Hu Y, Mosley T, et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk in Communities) study. *J Am Coll Cardiol*. 2010 Apr 13;55(15):1600-7.
- 21 Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. *Eur Heart J*. 2006 Nov;27(21):2588-605.
- 22 Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet*. 2010 Jun 12;375(9731):2073-81.
- 23 León Alvarez JL, Pérez Caballero MD. Experiencia con el paciente en la consulta especializada de hipertensión arterial complicada. *Rev Cubana Med*. 2009;48(4):182-92.

- 24 León Álvarez JL, Pérez Caballero MD, Suardíaz Martínez L. Hipertensión Arterial Complicada. Manual de Prácticas Médicas H.C.Q. "Hermanos Ameijeiras" IV Edición. Editores científicos: Héctor Rodríguez Silva, José Antonio Negrín Villavicencio (Ed), La Habana: Editorial Ciencias Médicas, 2013. ISBN: 978-959-212-859-0
- 25 León Alvarez JL, Pérez Caballero MD, Guerra Ibáñez G. Cinco años de experiencia en consulta especializada de hipertensión arterial complicada (2008-2012). Rev Cub Med. 2013;52(4):254-64.
- 26 Calderón C, Balagué L, Cortada JM, Sánchez A. Health promotion in primary care: How should we intervene? A qualitative study involving both physicians and patients. BMC Health Serv Res. 2011 Mar 23;11:62.
- 27 Bancalari Rodrigo CD, Martínez-Aguayo A, Aglony M, Zamorano J, Cerda V, Fernández M, et al. Prevalencia de hipertensión arterial y su asociación con la obesidad en edad pediátrica. Rev méd Chile [Internet]. 2011 Jul [citado 2017 Feb 04];139(7): 872-879. Disponible en: <http://dx.doi.org/10.4067/S003498872011000700007>
- 28 Bassareo PP, Mercurio G. Pediatric hypertension: An update on a burning problem. World J Cardiol. 2014 May 26;6(5):253-9.
- 29 Crouch R, Wilson A, Newbury J. A systematic review of the effectiveness of primary health education or intervention programs in improving rural women's knowledge of heart disease risk factors and changing lifestyle behaviours. Int J Evid Based Healthc. 2011 Sep;9(3):236-45.
- 30 Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 Oct 20;120(16):1640-5.
- 31 Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity

- and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. *Circulation*. 2006 Feb 14;113(6):898-918.
- 32 Elmer PJ, Grimm R Jr, Laing B, Grandits G, Svendsen K, Van Heel N, et al. Lifestyle intervention: results of the treatment of mild hypertension study (TOMHS). *Prev Med*. 1995 Jul;24(4):378-88.
- 33 Farsalinos K, Cibella F, Caponnetto P, Campagna D, Bhagwanji Morjaria J, Battaglia E, et al. Effect of continuous smoking reduction and abstinence on blood pressure and heart rate in smokers switching to electronic cigarettes. *Intern Emerg Med*. 2016 Feb;11(1):85-94.
- 34 Draijer R, de Graaf Y, Slettenaar M, de Groot E, Wright CI. Consumption of a Polyphenol-Rich Grape-Wine Extract Lowers Ambulatory Blood Pressure in Mildly Hypertensive Subjects. *Nutrients*. 2015 Apr 30;7(5):3138-53.
- 35 Neter J., Stam BE., Kok FJ., Grobbee DE., Geleijnse J. Influence of Weight Reduction on Blood Pressure A Meta-Analysis of Randomized Controlled Trials. *Hypertension*. 2003 Nov;42(5):878-84.
- 36 Hodgson JM, Croft KD, Woodman RJ, Puddey IB, Bondonno CP, Wu JH et al. Effects of vitamin E, vitamin C and polyphenols on the rate of blood pressure variation: results of two randomised controlled trials. *Br J Nutr*. 2014 Nov 14;112(9):1551-61.
- 37 Ras RT, Zock PL, Zebregs YE, Johnston NR, Webb DJ, Draijer R. Effect of polyphenol-rich grape seed extract on ambulatory blood pressure in subjects with pre- and stage I hypertension. *Br J Nutr*. 2013 Dec;110(12):2234-41.
- 38 Turnbull F, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. *Lancet*. 2003 Nov 8;362(9395):1527-35.
- 39 Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni. E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. *J Hypertens*. 2009 Nov;27(11):2121-58.

- 40 Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, et al. Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. *N Engl J Med.* 2006;354:1685-97.
- 41 Luders S, Schrader J, Berger J, Unger T, Zidek W, Bohn M, et al. The PHARAO Study: prevention of hypertension with the angiotensin converting enzyme inhibitor ramipril in patients with high normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. *J Hypertens.* 2008 Jul;26(7):1487-96.
- 42 The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *N Engl J Med.* 2000;342:145-53.
- 43 The EUROpean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). *Lancet.* 2003;362:782-8.
- 44 Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al. CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. *JAMA.* 2004 Nov 10;292(18):2217-25.
- 45 Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and stroke. *Kidney Int.* 2002;61:1086-97.
- 46 Atkins RC, Briganti EM, Lewis JB, Hunsicker LG, Braden G, Champion de Crespigny PJ, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. *Am J Kidney Dis.* 2005;45:281-7.
- 47 The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting

- enzyme inhibitors? A meta-analysis of individual patient data. *Ann Intern Med.* 2001;134:370-9.
- 48 Parving HH, Hommel E, Jensen BR, Hansen HP. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. *Kidney Int.* 2001;60:228-34.
- 49 Jaffe MG, Lee GA, Young JD, Sidney S, Go AS. Improved blood pressure control associated with a large-scale hypertension program. *JAMA.* 2013 Aug 21;310(7):699-705.
- 50 Go AS, Bauman MA, Coleman King SM, Fonarow GC, Lawrence W, Williams KA, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. *J Am Coll Cardiol.* 2014 Apr 1;63(12):1230-8.
- 51 Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. *Hypertension.* 2011 Apr; 57(4):689-94.
- 52 Ernst ME, Neaton JD, Grimm RH Jr, Collins G, Thomas W, Soliman EZ, et al. Multiple Risk Factor Intervention Trial Research Group. Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial. *Hypertension.* 2011 Dec;58(6):1001-7.
- 53 Dhakam Z, Yasmin, Mc Eniery CM, Burton T, Brown MJ, Wilkinson IB. A comparison of atenolol and nebivolol in isolated systolic hypertension. *J Hypertens.* 2008 Feb;26(2):351-6.
- 54 Kampus P, Serg M, Kals J, Zagura M, Muda P, Karu K, et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. *Hypertension.* 2011 Jun;57(6):1122-8.
- 55 Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes

- Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. *Lancet*. 2005 Sep 10-16;366(9489):895-906.
- 56 PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. *Lancet*. 2001 Sep 29;358(9287):1033-41.
- 57 Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med*. 2000 Jan 20;342(3):145-53.
- 58 Fox KM; EUROpean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). *Lancet*. 2003 Sep 6;362(9386):782-8.
- 59 León Alvarez JL. (2012). *New Therapeutics in Hypertension, Antihypertensive Drugs*, Prof. Hossein Babaei (Ed.), (pp.1-28). ISBN: 978-953-51-0462-9, InTech, Available from: <http://www.intechopen.com/books/antihypertensive-drugs/new-therapeutics-in-hypertension>
- 60 Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes. *N Engl J Med*. 2012 Dec 6;367(23):2204-13.
- 61 Gheorghide M, Böhm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, et al. Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure The ASTRONAUT Randomized Trial. *JAMA*. 2013 March 20;309(11):1125-35.
- 62 Rossitto G, Kumath G, Messerli FH. Should alpha blockers ever be used as antihypertensive drugs. *Cleve Clin J Med*. 2010 Dec;77(12):884-8.
- 63 ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). *JAMA*. 2000 April 19;283(15):1967-75.

- 64 Vongpatanasin W, Kario K, Atlas SA, Victor RG. Central sympatholytic drugs. *J Clin Hypertens* (Greenwich). 2011 Sep;13(9):658-61.
- 65 Materson BJ. Central and peripheral sympatholytics. En: Izzo JL, Black HR, editors. *Hypertension Primer*, 3th ed. Dallas: Lippincott Williams & Willkins; 2003. p. 423-5.
- 66 Cohn JN, Mc Iness GT, Shepard AM. Direct acting vasodilators. *J Clin Hypertens* (Greenwich). 2011 Sep;13(9):690-2.
- 67 National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The Fourth Report on the diagnosis, evaluation, and treatment of High Blood Pressure in Children and Adolescents. *Pediatrics*. 2004 Aug;114(2 Suppl 4th Report):555-76.
- 68 Lurbe E, Cifkova R, Cruickshank JK, Dillon MJ, Ferreira I, Invitti C, et al. Manejo de la hipertensión arterial en niños y adolescentes: recomendaciones de la Sociedad Europea de Hipertensión. *An Pediatr (Barc)*. 2010; 73(1):51. e1-51. e28.
- 69 Llapur R, González R. Hipertensión arterial en niños y adolescentes. *Rev Cubana Pediatr*. 2015;87(2):135-9.
- 70 Riley M, Bluhm B. High Blood Pressure in Children and Adolescents. *Am Fam Physician*. 2012 Apr 1;85(7):693-700.
- 71 Lurbe E, Álvarez J, Redon J. Diagnosis and Treatment of Hypertension in Children. *Curr Hypertens Rep*. 2010 Dec;12(6):480-6.
- 72 Lurbe E, Agabiti-Rosei E, Cruickshank JK, Dominiczak A, Erdine S, Hirth A, et al. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. *J Hypertens*. 2016 Oct;34(10):1887-920.
- 73 Kapur G, Baracco R. Evaluation of Hypertension in Children. *Curr Hypertens Rep*. 2013 Oct;15(5):433-43.
- 74 Boneparth A, Flynn JT. Evaluation and Treatment of Hypertension in General Pediatric Practice. *Clin Pediatr (Phila)*. 2009 Jan;48(1):44-9.
- 75 Feber J, Ahmed M. Hypertension in children: new trends and challenges. *Clin Sci (Lond)*. 2010 May 14;119(4):151-61.

- 76 Czarniak P, Zurowska A. Treatment Strategies to Prevent Renal Damage in Hypertensive Children. *Curr Hypertens Rep*. 2014 Apr;16(4):423.
- 77 Zayas Somoza E, García Iraola M, Raola Sánchez ME. Algunas consideraciones sobre la fisiopatología de la hipertensión arterial del adulto mayor. *Geriatría: Revista Iberoamericana de Geriatria y Gerontología*. 1999 May;15 (5):25-30.
- 78 Qaseem A, Wilt TJ, Rich R, Humphrey LL, Frost J, Forciea MA, et al. Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets: A Clinical Practice Guideline From the American College of Physicians and the American Academy of Family Physicians. *Ann Intern Med*. 2017 Jan 17. doi: 10.7326/P16-9030. [Epub ahead of print]
- 79 James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014 Feb 5;311(5):507-20.
- 80 Hage FG, Mansur SJ, Xing D, Oparil S. Hypertension in women. *Kidney Int Suppl* (2011). 2013 Dec;3(4):352-6.
- 81 Navarro DA. Menopausia e hipertensión arterial de la biología a la práctica. *Rev cubana med [Internet]*. 2015 Sep [citado 2017 Feb 04];54(3). Disponible en: <http://scielo.sld.cu/scielo.php?script=sciarttext&pid=S003475232015000300006&lng=es>
- 82 Ojeda NB, Intapad S, Alexander BT. Sex differences in the developmental programming of hypertension. *Acta Physiol (Oxf)*. 2014 Feb;210(2):307-16.
- 83 Pacheco-Romero J. Hipertensión arterial en diferentes edades de la mujer. *Hipertensión arterial en diferentes edades de la mujer. An Fac med*. 2010;71(4):257-64.
- 84 Maric-Bilkan C, Gilbert E, Ryan MJ. Impact of ovarian function on cardiovascular health in women: focus on hypertension. *International. Int J Womens Health*. 2014 Jan 24;6:131-9.
- 85 Navarro Despaigne D, Ledesma Osorio Y. Menopausia, hipertensión arterial y terapia de reemplazo hormonal. *Rev Cubana Endocrinol [Internet]*. 2003 Abr

[citado 2017 Feb 04];14(1). Disponible en:
http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S15612953200300010000&lng=es.

- 86 Soriano Fernández H, Rodenas García L, Moreno Escribano D. Criterios de Elegibilidad de Métodos Anticonceptivos. Nuevas Recomendaciones. Rev Clin Med Fam [Internet]. 2010 Oct [citado 2017 Feb 04];3(3):206-16. Disponible en: <http://scielo.isciii.es/scielo.php?script=sciarttext&pid=S1699695X2010000300009&lng=es>
- 87 Redman CW. Fetal outcome in trial of antihypertensive treatment in pregnancy. Lancet. 1976 Oct 9;2(7989):753-6.
- 88 Cockburn J, Moar VA, Ounsted M, Redman CW. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet. 1982 Mar 20;1(8273):647-9.
- 89 Tagle R, Acevedo M, Valdés G. Hipertensión arterial en la mujer adulta. Rev. méd. Chile [Internet]. 2013 Feb [citado 2017 Feb 04];141(2):237-47. Disponible en: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S003498872013000200014&lng=es
- 90 Zambrana RE, López L, Dinwiddie GY, Ray RM, Phillips LS, Trevisan M, et al. Prevalence and Incident Prehypertension and Hypertension in Postmenopausal Hispanic Women: Results from the Women's Health Initiative. Am J Hypertens. 2014 Mar;27(3):372-81.
- 91 Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, Ferreira R, Foidart JM, et al. Guía de práctica clínica de la ESC para el tratamiento de las enfermedades cardiovasculares durante el embarazo. Rev Esp Cardiol. 2012;65(2):171.e1-e44.
- 92 American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013 Nov;122(5):1122-31.

- 93 Carson AP, Howard G, Burke GL, Shea S, Levitan EB, Muntner P. Ethnic differences in hypertension incidence among middle-aged and older adults: the multi-ethnic study of atherosclerosis. *Hypertension*. 2011 Jun;57(6):1101-7.
- 94 Selassie A, Wagner CS, Laken ML, Ferguson ML, Ferdinand KC, Egan BM. Progression is accelerated from prehypertension to hypertension in blacks. *Hypertension*. 2011 Oct;58(4):579-87.
- 95 Howard G, Lackland DT, Kleindorfer DO, Kissela BM, Moy CS, Judd SE, et al. Racial differences in the impact of elevated systolic blood pressure on stroke risk. *JAMA Intern Med*. 2013 Jan 14;173(1):46-51.
- 96 Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm RH Jr, et al. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. *Hypertension*. 2010 Nov;56(5):780-800.
- 97 Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. *Arch Intern Med*. 2005 Jun 27;165(12):1410-9.
- 98 Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. *Lancet*. 2007 Apr 7;369(9568):1208-19.
- 99 American Diabetes Association. Standards of medical care in Diabetes-2017. *Diabetes Care*. 2017 Jan;40(Suppl 1):S4-S5.
- 100 Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. *Ann Intern Med*. 2013 Jun 4;158(11):825-30.
- 101 Alfonzo Guerra JP. Prehipertensión. Mito o realidad. *Rev Cubana Med*. 2011;50(3):289-301.
- 102 Alfonzo JP, Ugarte C, Banasco J, Fraxedas R, Gutiérrez F, Lahera J. Renovascular hypertension in children and adolescents: diagnosis and treatment over 19 years. *Nefrología*. 2006;26(5):573-80.

- 103 Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. *BMJ*. 2009 May 19;338:b1665.
- 104 Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double blind, long term trial. *Circulation*. 2002 Nov 5;106(19):2422-7.
- 105 Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Niemenen MS, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan vs. atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. *Circulation*. 2003 Aug 12;108(6):684-690.
- 106 Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. *Hypertension*. 2009 Nov;54(5):1084-91.
- 107 Devereux RB, Wachtell K, Gerds E, Boman K, Niemenen MS, Papademetriou V, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. *JAMA*. 2004 Nov 17; 292(19):2350-6.
- 108 Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. *N Engl J Med*. 2004 Nov 11;351(20):2058-68.
- 109 Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. *Rev Esp Cardiol (Engl Ed)*. 2016 Oct;69(10):939.
- 110 Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). *Eur Heart J*. 2007 Oct;28(19):2375-414.

- 111 European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). *Eur Heart J*. 2010 Oct;31(19):2369-429.
- 112 Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. *J Am Coll Cardiol*. 2011 Sep 20;58(13):1378-85.
- 113 Gupta BP, Murad MH, Clifton MM, Prokop L, Nehra A, Kopecky SL. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. *Arch Intern Med*. 2011 Nov 14; 171(20):1797-803.
- 114 Manolis A, Doulas M. Sexual dysfunction: the 'prima ballerina' of hypertension related quality of-life complications. *J Hypertens*. 2008 Nov;26(11):2074-84.
- 115 Pickering TG, Shepherd AM, Puddey I, Glasser DB, Orazem J, Sherman N, et al. Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial. *Am J Hypertens*. 2004 Dec;17(12 Pt 1):1135-42.
- 116 Scranton RE, Lawler E, Botteman M, Chittamooru S, Gagnon D, Lew R, et al. Effect of treating erectile dysfunction on management of systolic hypertension. *Am J Cardiol*. 2007 Aug 1;100(3):459-63.
- 117 Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK, Aznaouridis KA, Stefanadis CI. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. *Circ Cardiovasc Qual Outcomes*. 2013 Jan 1;6(1):99-109.
- 118 Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. *Hypertension*. 2008 Jun;51(6):1403-19.

- 119 Acelajado MC, Pisoni R, Dudenbostel T, Dell'Italia LJ, Cartmill F, Zhang B, et al. Refractory hypertension: definition, prevalence, and patient characteristics. *J Clin Hypertens (Greenwich)*. 2012 Jan;14(1):7-12.
- 120 Calhoun DA, Booth JN 3rd, Oparil S, Irvin MR, Shimbo D, Lackland DT, et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. *Hypertension*. 2014 Mar;63(3):451-8.
- 121 Sander GE, Giles TD. Resistant Hypertension: Concepts and Approach to Management. *Curr Hypertens Rep*. 2011 Oct;13(5):347-55.
- 122 Pimienta E. Update on Diagnosis and Treatment of Resistant Hypertension. *Iran J Kidney Dis*. 2011 Jul;5(4):215-27.
- 123 Del Pozo Jerez HA, Leiva Suero LE. Atención pre-quirúrgica del hipertenso eventual. *Rev Cubana Med [Internet]*. 1998 Sep [citado 2017 Feb 28]; 37(3):141-6. Disponible en: <http://scielo.sld.cu/scielo.php?script=sciarttext&pid=S0034-75231998000300003&lng=es>
- 124 Del Pozo Jerez HA, Leiva Suero LE, Jiménez Paneque R, Macías Castro I. Proposición de un método alternativo para diagnosticar control tensional estable en el hipertenso. *Rev Cubana Med [Internet]*. 1999 Jun [citado 2017 Feb 28];38(2):105-110. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S003475231999000200003&lng=es
- 125 Wallace AW, Au S, Cason BA. Perioperative β -blockade: atenolol is associated with reduced mortality when compared to metoprolol. *Anesthesiology*. 2011 Apr;114(4):824-36.
- 126 Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014 Jun 24;129(25 Suppl 2): S1-45.

- 127 Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, et al. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. *N Engl J Med*. 2016 May 26;374(21):2021-31.
- 128 Yusuf S, Lonn E, Pais P, Bosch J, López-Jaramillo P, Zhu J, et al. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. *N Engl J Med*. 2016 May 26;374(21):2032-43.
- 129 Lonn EM, Bosch J, López-Jaramillo P, Zhu J, Liu L, Pais P, et al. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. *N Engl J Med*. 2016 May 26;374(21):2009-20.
- 130 Lonn E, Bosch J, Pogue J, Avezum A, Chazova I, Dans A, et al. Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. *Can J Cardiol*. 2016 Mar;32(3):311-8.
- 131 Cushman WC, Goff DC Jr. More HOPE for Prevention with Statins. *N Engl J Med*. 2016 May 26;374(21):2085-7.
- 132 Pérez Caballero MD, León Álvarez JL, Fernández Arias MA. El control de la hipertensión arterial: un problema no resuelto. *Rev Cubana Med*. 2011;50(3).

Hospital Clínico Quirúrgico "Hermanos Ameijeiras". San Lázaro 701, entre Belascoaín y Marqués González. Centro Habana. La Habana. Cuba. CP: 10300

Correo electrónico: jorge.leon@infomed.sld.cu Teléfono: 78761000